ClinicalTrials.gg
CompletedNCT02706951Updated Jan 30, 2024Results posted

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

A Phase 3 interventional study of Methotrexate and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 153 sites in 25 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
648
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
4th of 19
648 · median 300
Started
2016
with 3 others
Phase 3
7 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to MTX.

The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.

Read the detailed description

The study includes a 35-day screening period; a 14-week randomized, double-blind, parallel-group, controlled treatment period (Period 1); a 246-week blinded extension period (Period 2); and a 30-day follow-up visit.

Participants who met eligibility criteria were to be randomized in a 2:2:1:1 ratio to one of four treatment groups:

  • Group 1: upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
  • Group 2: upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
  • Group 3: MTX (Period 1) → upadacitinib 30 mg QD (Period 2)
  • Group 4: MTX (Period 1) → upadacitinib 15 mg QD (Period 2)

Starting with implementation of Protocol Amendment 5, all participants in the extension period will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Musculoskeletal Disease
  • Arthritis
  • Joint Disease
  • Anti-inflammatory agents
  • Antirheumatic agents
  • Upadacitinib
  • ABT-494
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA for >= 3 months.
  • Subjects must have been on oral or parenteral MTX therapy >= 3 months and on a stable dose for >= 4 weeks prior to first dose of study drug.
  • Must have discontinued all conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (other than MTX) >= 4 weeks prior to first dose of study drug.
  • Meets the following minimum disease activity criteria: >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
  • Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).
  • Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
648 participants (actual)

Study arms

  • Experimental
    Upadacitinib 30 mg

    Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.

    Drug: Upadacitinib · Drug: Placebo Methotrexate

  • Experimental
    Upadacitinib 15 mg

    Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.

    Drug: Upadacitinib · Drug: Placebo Methotrexate

  • Experimental
    Methotrexate / Upadacitinib 30 mg

    Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks. Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.

    Drug: Methotrexate · Drug: Upadacitinib · Drug: Placebo Upadacitinib · Drug: Placebo Methotrexate

  • Experimental
    Methotrexate / Upadacitinib 15 mg

    Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks. Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.

    Drug: Methotrexate · Drug: Upadacitinib · Drug: Placebo Upadacitinib · Drug: Placebo Methotrexate

Interventions

  • Capsule; Oral

  • Tablet; Oral

    Also known as: ABT-494, Rinvoq

  • DrugPlacebo Upadacitinib

    Tablet; Oral

  • DrugPlacebo Methotrexate

    Capsule; Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14

    The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 14. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and week 14

  2. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14

    The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 14. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

    Time frame: Week 14

Secondary outcomes

  1. Change From Baseline in in Disease Activity Score 28 (CRP) at Week 14

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.

    Time frame: Baseline to week 14

  2. Change From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline to week 14

  3. Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 14

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

    Time frame: Baseline to week 14

  4. Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 14

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Week 14

  5. Change From Baseline in Duration of Morning Stiffness at Week 14

    Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.

    Time frame: Baseline to week 14

  6. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 14

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and week 14

  7. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 14

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and week 14

07

Results

Posted Oct 7, 2019

Participant flow

A total of 648 participants with rheumatoid arthritis (RA) on a stable dose of methotrexate (MTX) were randomized at 138 study sites located in 24 countries.

Period 1
Participant flow — Period 1
MilestonePeriod 1: MethotrexatePeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mgPeriod 2: Upadacitinib 30 mg
Started21621721500
Completed20320120500
Not completed13161000
Withdrew: Adverse event15300
Withdrew: Withdrawal by subject106600
Withdrew: Lost to follow-up04100
Withdrew: Other21000
Period 2
Participant flow — Period 2
MilestonePeriod 1: MethotrexatePeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mgPeriod 2: Upadacitinib 30 mg
Started000302300
Completed000184180
Not completed000118120
Withdrew: Adverse event0002534
Withdrew: Withdrawal by subject0003844
Withdrew: Lost to follow-up000179
Withdrew: Covid-19 related00012
Withdrew: Other0003731

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14

The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 14. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and week 14
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14
percentage of participantsMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1441.2 (34.6 to 47.8)67.7 (61.5 to 74.0)71.2 (65.1 to 77.2)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 26.5 · 95% CI 17.5 to 35.6Response Rate Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 30.0 · 95% CI 21.0 to 38.9Response Rate Difference = Upadacitinib - Methotrexate
PrimaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14

The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 14. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14
percentage of participantsMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 1419.4 (14.2 to 24.7)44.7 (38.1 to 51.3)53.0 (46.4 to 59.7)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 25.3 · 95% CI 16.8 to 33.7Response Rate Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 33.6 · 95% CI 25.1 to 42.1Response Rate Difference = Upadacitinib - Methotrexate
SecondaryChange From Baseline in in Disease Activity Score 28 (CRP) at Week 14

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.

Time frame:
Baseline to week 14
Reported as:
Least squares mean · scores on a scale
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 14
scores on a scaleMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 14-1.20 (-1.39 to -1.01)-2.29 (-2.48 to -2.10)-2.61 (-2.80 to -2.41)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Least squares (ls) mean difference: -1.08 · 95% CI -1.32 to -0.85Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -1.40 · 95% CI -1.64 to -1.17Difference = Upadacitinib - Methotrexate
SecondaryChange From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline to week 14
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14
scores on a scaleMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14-0.32 (-0.41 to -0.23)-0.65 (-0.73 to -0.56)-0.73 (-0.82 to -0.64)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -0.33 · 95% CI -0.43 to -0.22Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -0.41 · 95% CI -0.51 to -0.30Difference = Upadacitinib - Methotrexate
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 14

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

Time frame:
Baseline to week 14
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 14
scores on a scaleMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 144.32 (3.19 to 5.44)8.28 (7.17 to 9.40)10.19 (9.07 to 11.30)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 3.97 · 95% CI 2.52 to 5.42Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 5.87 · 95% CI 4.42 to 7.32Difference = Upadacitinib - Methotrexate
SecondaryPercentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 14

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 14
percentage of participantsMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 148.3 (4.6 to 12.0)28.1 (22.1 to 34.1)40.5 (33.9 to 47.0)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 19.8 · 95% CI 12.8 to 26.8Response Rate Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 32.1 · 95% CI 24.6 to 39.7Response Rate Difference = Upadacitinib - Methotrexate
SecondaryChange From Baseline in Duration of Morning Stiffness at Week 14

Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.

Time frame:
Baseline to week 14
Reported as:
Least squares mean · minutes
Change From Baseline in Duration of Morning Stiffness at Week 14
minutesMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Duration of Morning Stiffness at Week 14-53.03 (-72.18 to -33.88)-94.56 (-113.57 to -75.54)-102.34 (-121.24 to -83.45)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = 0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -41.53 · 95% CI -66.56 to -16.50Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -49.31 · 95% CI -74.23 to -24.40Difference = Upadacitinib - Methotrexate
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 14

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and week 14
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 14
percentage of participantsMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 1415.3 (10.5 to 20.1)41.9 (35.4 to 48.5)52.1 (45.4 to 58.8)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (This comparison was not part of the pre-specified multiplicity testing sequence; the nominal p-value is reported.) · Response rate difference: 26.7 · 95% CI 18.5 to 34.8Response Rate Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (This comparison was not part of the pre-specified multiplicity testing sequence; the nominal p-value is reported.) · Response rate difference: 36.8 · 95% CI 28.6 to 45.0Response Rate Difference = Upadacitinib - Methotrexate
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 14

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and week 14
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 14
percentage of participantsMethotrexateUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 142.8 (0.6 to 5.0)22.6 (17.0 to 28.1)33.0 (26.7 to 39.3)
Statistical analysis
  • Methotrexate vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (This comparison was not part of the pre-specified multiplicity testing sequence; the nominal p-value is reported.) · Response rate difference: 19.8 · 95% CI 13.8 to 25.8Response Rate Difference = Upadacitinib - Methotrexate
  • Methotrexate vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (This comparison was not part of the pre-specified multiplicity testing sequence; the nominal p-value is reported.) · Response rate difference: 30.2 · 95% CI 23.6 to 36.9Response Rate Difference = Upadacitinib - Methotrexate

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Methotrexate0/216 (0%)7/216 (3.2%)49/216 (22.7%)
Period 1: Upadacitinib 15 mg0/217 (0%)11/217 (5.1%)43/217 (19.8%)
Period 1: Upadacitinib 30 mg0/215 (0%)6/215 (2.8%)51/215 (23.7%)
Periods 1+2: Upadacitinib 15 mg7/318 (2.2%)95/318 (29.9%)219/318 (68.9%)
Periods 1+ 2: Upadacitinib 30 mg5/311 (1.6%)75/311 (24.1%)211/311 (67.8%)
Period 2: Upadacitinib 15 mg Switched From Upadacitinib 30 mg4/205 (2%)22/205 (10.7%)82/205 (40%)
Most frequent serious events
Showing 10 of 177
Most frequent serious events
EventPeriod 1: MethotrexatePeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriods 1+2: Upadacitinib 15 mgPeriods 1+ 2: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mg Switched From Upadacitinib 30 mg
PneumoniaInfections and infestations0/2160/2170/21512/3184/3110/205
COVID-19 pneumoniaInfections and infestations0/2160/2170/2158/3184/3117/205
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/2161/2171/2153/3185/3110/205
Atrial fibrillationCardiac disorders1/2161/2170/2155/3180/3110/205
OsteoarthritisMusculoskeletal and connective tissue disorders0/2160/2170/2155/3183/3112/205
Myocardial infarctionCardiac disorders0/2160/2171/2150/3184/3110/205
Humerus fractureInjury, poisoning and procedural complications0/2160/2171/2150/3184/3111/205
BronchitisInfections and infestations0/2160/2170/2154/3182/3110/205
COVID-19Infections and infestations0/2160/2170/2153/3180/3112/205
Respiratory failureRespiratory, thoracic and mediastinal disorders0/2160/2170/2150/3180/3112/205
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPeriod 1: MethotrexatePeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriods 1+2: Upadacitinib 15 mgPeriods 1+ 2: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mg Switched From Upadacitinib 30 mg
Blood creatine phosphokinase increasedInvestigations0/2165/2179/21532/31858/3117/205
NasopharyngitisInfections and infestations7/2164/2174/21556/31838/3117/205
Urinary tract infectionInfections and infestations5/21610/21710/21543/31847/31113/205
Upper respiratory tract infectionInfections and infestations13/2169/2176/21538/31846/3115/205
Rheumatoid arthritisMusculoskeletal and connective tissue disorders10/2161/2175/21545/31829/3119/205
BronchitisInfections and infestations7/2164/2174/21539/31840/3115/205
Herpes zosterInfections and infestations1/2163/2175/21532/31832/3116/205
COVID-19Infections and infestations0/2160/2170/21521/3182/31120/205
HypertensionVascular disorders4/2165/2170/21528/31825/3116/205
Latent tuberculosisInfections and infestations0/2160/2170/21525/31816/3115/205

Baseline characteristics

The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean55.3 ± 11.1254.5 ± 12.2053.1 ± 12.7254.3 ± 12.05
Age, Customized
Age, Customized(Participants)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 40 years23283182
40 - 64 years148147141436
≥ 65 years454243130
Sex: Female, Male
Sex: Female, Male(Participants)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
Female179174170523
Male374345125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino505254156
Not Hispanic or Latino166165161492
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
White176173180529
Black or African American1115935
American Indian/Alaska Native34310
Asian24242169
Multiple2125
Geographic Region
Geographic Region(Participants)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
North America646464192
South/Central America31303091
Western Europe88824
Eastern Europe798080239
Asia - Japan22222165
Other12131237
Duration of RA Diagnosis
Duration of RA Diagnosis(years)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean5.8 ± 6.637.5 ± 8.886.5 ± 6.986.6 ± 7.58
Tender Joint Count
Tender Joint Count(joints)MethotrexateUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean25.2 ± 15.9924.5 ± 15.1024.8 ± 15.1924.8 ± 15.41

7 further baseline measures are reported on the registry.

08

Study locations

153 sites
  • Rheum Assoc of North Alabama /ID# 146009
    Huntsville, Alabama 35801, United States
  • Alabama Medical Group, PC /ID# 153941
    Mobile, Alabama 36608-1787, United States
  • ArthroCare Arthritis Care & Re /ID# 143751
    Gilbert, Arizona 85234, United States
  • Elite Clinical Studies, LLC /ID# 143760
    Phoenix, Arizona 85018, United States
  • University of Arizona Cancer Center - North Campus /ID# 147175
    Tucson, Arizona 85719-1478, United States
  • NEA Baptist Womens Clinic /ID# 148904
    Jonesboro, Arkansas 72401, United States
  • C.V. Mehta MD, Med Corporation /ID# 143762
    Hemet, California 92543, United States
  • Arthritis Assoc & Osteo Ctr /ID# 147176
    Colorado Springs, Colorado 80920, United States
  • Ctr Rheum, Immuno, Arthritis /ID# 143766
    Fort Lauderdale, Florida 33309, United States
  • South Florida Research Ph I-IV /ID# 151983
    Miami Springs, Florida 33166-7225, United States
  • Advent Clinical Research /ID# 143767
    Pinellas Park, Florida 33781, United States
  • Sarasota Arthritis Center /ID# 146011
    Sarasota, Florida 34239, United States
  • W. Broward Rheum Assoc Inc. /ID# 146010
    Tamarac, Florida 33321, United States
  • Clinical Research West FL /ID# 148726
    Tampa, Florida 33603, United States
  • SW FL Clin Res Ctr, Tampa, FL /ID# 143763
    Tampa, Florida 33609, United States
  • University of South Florida /ID# 146004
    Tampa, Florida 33612, United States
  • BayCare Medical Group, Inc. /ID# 151985
    Tampa, Florida 33614-7101, United States
  • BayCare Medical Group, Inc. /ID# 163595
    Tampa, Florida 33614-7101, United States
  • Jefrey D. Lieberman, MD, P.C. /ID# 151816
    Decatur, Georgia 30033, United States
  • Great Lakes Clinical Trials /ID# 150935
    Chicago, Illinois 60640, United States
  • PRN Professional Research Network of Kansas, LLC /ID# 143761
    Wichita, Kansas 67205, United States
  • Ochsner Clinic Foundation /ID# 153573
    Baton Rouge, Louisiana 70836-6455, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 160809
    Monroe, Louisiana 71203, United States
  • Vanguard Medical Research, LLC /ID# 153124
    Shreveport, Louisiana 71011, United States
  • Mansfield Health Center /ID# 161627
    Mansfield, Massachusetts 02048, United States
  • Quality Clinical Research Inc. /ID# 156415
    Omaha, Nebraska 68114, United States
  • Dartmouth-Hitchcock Medical Center /ID# 146008
    Lebanon, New Hampshire 03756, United States
  • Albuquerque Clinical Trials, Inc /ID# 147618
    Albuquerque, New Mexico 87102, United States
  • Arthritis and Osteo Assoc /ID# 147177
    Las Cruces, New Mexico 88011, United States
  • Coastal Carolina Health Care /ID# 149275
    New Bern, North Carolina 28562, United States
  • STAT Research, Inc. /ID# 143770
    Vandalia, Ohio 45377-9464, United States
  • Health Research Oklahoma /ID# 159550
    Oklahoma City, Oklahoma 73103-2400, United States
  • Healthcare Research Consultant /ID# 147632
    Tulsa, Oklahoma 74135, United States
  • Innovative Clinical Research /ID# 143757
    Greenville, South Carolina 29601, United States
  • Nashville Arthritis and Rheumatology /ID# 162641
    Nashville, Tennessee 37203, United States
  • Tekton Research, Inc. /ID# 159554
    Austin, Texas 78745, United States
  • Diagnostic Group Integrated He /ID# 148725
    Beaumont, Texas 77701, United States
  • Trinity Universal Res Assoc /ID# 150138
    Carrollton, Texas 75007, United States
  • Arth and Osteo Clin Brazo Valley /ID# 160810
    College Station, Texas 77845, United States
  • Adriana Pop-Moody MD Clinic PA /ID# 147627
    Corpus Christi, Texas 78404, United States
  • Accurate Clinical Management /ID# 143768
    Houston, Texas 77004, United States
  • Accurate Clinical Research /ID# 143769
    Houston, Texas 77089, United States
  • Pioneer Research Solutions, Inc. /ID# 143765
    Houston, Texas 77098-5294, United States
  • P&I Clinical Research /ID# 151358
    Lufkin, Texas 75904-3132, United States
  • SW Rheumatology Res. LLC /ID# 147620
    Mesquite, Texas 75150, United States
  • Sun Research Institute /ID# 159553
    San Antonio, Texas 78215, United States
  • Arthritis Clinic of Central TX /ID# 149266
    San Marcos, Texas 78666, United States
  • Adv Rheumatology of Houston /ID# 162609
    The Woodlands, Texas 77382, United States
  • DM Clinical Research /ID# 151359
    Tomball, Texas 77375, United States
  • Arthritis & Osteoporosis Clinic /ID# 143752
    Waco, Texas 76710, United States
  • Ctr for Arth and Rheum Disease /ID# 143759
    Chesapeake, Virginia 23320, United States
  • Aurora Rheumatology and Immunotherapy Center /ID# 160811
    Franklin, Wisconsin 53132, United States
  • Mautalen Salud e Investigacion /ID# 145980
    Buenos Aires, 1128, Argentina
  • Ctr Privado Med Familiar /ID# 149183
    Buenos Aires, 1417, Argentina
  • Consultorio Reumatologic Pampa /ID# 145979
    Buenos Aires, 1428, Argentina
  • Centro de Educación Médica e Investigaciones Clínicas "Norberto Quimo" - CEMIC /ID# 149176
    Buenos Aires, 1431, Argentina
  • Cordis S.A. /Id# 152621
    Salta, 4400, Argentina
  • Centro de Enfermedades /ID# 153543
    Santa Fe, 2000, Argentina
  • Royal Prince Alfred Hospital /ID# 146028
    Camperdown, New South Wales 2050, Australia
  • Rheuma-Zentrum Wien-Oberlaa /ID# 144728
    Wien, 1100, Austria
  • Algemeen Stedelijk Ziekenhuis /ID# 148720
    Aalst, Oost-Vlaanderen 9300, Belgium
  • ReumaClinic Genk /ID# 146030
    Genk, 3600, Belgium
  • Diag Consult Ctr 17 Sofia EOOD /ID# 144730
    Sofia, 1505, Bulgaria
  • UMHAT Sv. Ivan Rilski /ID# 147351
    Sofia, 1612, Bulgaria
  • Reg. Clinical Hosptial Concepcion /ID# 151267
    Concepcion, 4070038, Chile
  • Quantum Research LTDA. /ID# 145984
    Puerto Varas, 5550170, Chile
  • Quantum Research Stgo. /ID# 145983
    Santiago, 7500588, Chile
  • CTCenter MaVe, s.r.o. /ID# 144823
    Olomouc, Olomoucky Kraj 779 00, Czechia
  • Nuselská poliklinika, Revmatologie /ID# 145986
    Prague 4, Praha 4 140 00, Czechia
  • Thomayerova nemocnice /ID# 144736
    Prague 4, Praha 4 140 00, Czechia
  • RHEUMA s.r.o. /ID# 144737
    Breclav, 690 02, Czechia
  • Medical Plus, s.r.o. /ID# 144821
    Uherské Hradište, 686 01, Czechia
  • MediTrials /ID# 159745
    Tartu, Tartumaa 50406, Estonia
  • North Estonian Medical Centre /ID# 145455
    Tallinn, 13419, Estonia
  • General Hospital of Athens "Ippokratio" /ID# 144739
    Athens, 11527, Greece
  • Vital Medical Center Orvosi es /ID# 144740
    Veszprém, Veszprem 8200, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont /ID# 144743
    Budapest, 1134, Hungary
  • Pest Megyei Flor Ferenc Korhaz /ID# 144742
    Kistarcsa, 2143, Hungary
  • Fejer Megyei Szent Gyorgy Korh /ID# 144741
    Szekesfehervar, 8000, Hungary
  • Barzilai Medical Center /ID# 144744
    Ashkelon, 78278, Israel
  • Bnai Zion Medical Center /ID# 144745
    Haifa, 3339419, Israel
  • The Lady Davis Carmel MC /ID# 147174
    Haifa, 3436212, Israel
  • Sheba Medical Center /ID# 144824
    Ramat Gan, 5262100, Israel
  • Universita di Catanzaro Magna Graecia /ID# 144747
    Catanzaro, Calabria 88100, Italy
  • A.O.U.I. di Verona Policlinico /ID# 144746
    Verona, 37134, Italy
  • Kondo Clinic for Rheum & Ortho /ID# 148268
    Fukuoka-shi, Fukuoka 810-0001, Japan
  • NHO Kyushu Medical Center /ID# 148279
    Fukuoka-shi, Fukuoka 810-8563, Japan
  • NHO Kyushu Medical Center /ID# 148280
    Fukuoka-shi, Fukuoka 810-8563, Japan
  • Aso Iizuka Hospital /ID# 148272
    Iizuka-shi, Fukuoka 820-8505, Japan
  • Inoue Hospital /ID# 148069
    Takasaki, Gunma 3700053, Japan
  • Bay Side Misato Medical Center /ID# 148281
    Kochi-shi, Kochi 781-0112, Japan
  • Center for Arthritis and Clinical Rheumatology Matsubara Clinic /ID# 148269
    Kumamoto-shi, Kumamoto 862-0920, Japan
  • Kumamoto Shinto General Hospital /ID# 148286
    Kumamoto-shi, Kumamoto 8628655, Japan
  • Nagasaki University Hospital /ID# 149859
    Nagasaki-shi, Nagasaki 852-8501, Japan
  • Sasebo Chuo Hospital /ID# 148275
    Sasebo-city, Nagasaki 857-1195, Japan
  • Osaka Red Cross Hospital /ID# 148267
    Osaka-shi, Osaka 543-8555, Japan
  • Seirei Hamamatsu General Hosp /ID# 148270
    Hamamatsu, 430-8558, Japan
  • Ohira Orthopaedic Hospital /ID# 157944
    Hyuga, 883-0043, Japan
  • Shirahama Hamayu Hospital /ID# 148277
    Nishimura, 649-2211, Japan
  • Sanuki Municipal Hospital /ID# 158080
    Sanuki, 769-2321, Japan

Showing the first 100 of 153 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23. Erratum In: Lancet. 2019 Jun 29;393(10191):2590. doi: 10.1016/S0140-6736(19)31474-6. PubMed 31130260 ↗
  • Bergman M, Buch MH, Tanaka Y, Citera G, Bahlas S, Wong E, Song Y, Zueger P, Ali M, Strand V. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatol Ther. 2022 Dec;9(6):1517-1529. doi: 10.1007/s40744-022-00483-4. Epub 2022 Sep 20. PubMed 36125701 ↗
  • Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Adv Ther. 2021 Dec;38(12):5649-5661. doi: 10.1007/s12325-021-01930-4. Epub 2021 Oct 12. PubMed 34636000 ↗
  • Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. PubMed 34041702 ↗
  • Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford). 2021 Jul 1;60(7):3209-3221. doi: 10.1093/rheumatology/keaa770. PubMed 33313898 ↗
  • Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28. Erratum In: Ann Rheum Dis. 2021 May;80(5):e83. doi: 10.1136/annrheumdis-2020-218510corr1. PubMed 33115760 ↗
  • Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. PubMed 31610021 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2017, 18 months.

Results were first posted in Oct 2019, 2 years after primary completion. A results delay was requested in Sep 2018.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 18 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 11, 2016
StartActual
Mar 23, 2016
Primary completionActual
Oct 2, 2017
CompletionActual
Aug 10, 2022
Results delay requested
Sep 26, 2018
Results first posted
Oct 7, 2019
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02706951
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 11, 2016
Start date
Mar 23, 2016
Primary completion
Oct 2, 2017
Completion
Aug 10, 2022
Results posted
Oct 7, 2019
Last update
Jan 30, 2024

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion